乌罗立A可以通过激活PINK1/PRKN介导的线粒细胞吸收来缓解辐射性肺炎
Anqi Zhang1, Shilan Luo1, Peng Li1
1Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
International immunopharmacology
|April 20, 2025
概括
辐射性肺炎 (RP) 是由线粒体损伤引起的炎症引起的. 乌罗立A激活了线粒,清除受损的线粒体和减少炎症,显示了RP的治疗潜力.
科学领域:
- 细胞生物学 细胞生物学
- 免疫学 免疫学 免疫学
- 放射治疗研究 放射治疗研究
背景情况:
- 辐射性肺炎 (RP) 是放射治疗的严重并发症,涉及炎症和细胞损伤.
- 目前对RP的治疗方法有限,需要新的治疗策略.
- 这项研究探讨了线粒和干扰素反应在RP病变发生过程中的作用.
研究的目的:
- 调查RP中辐射诱导的PINK1/PRKN介导的线粒和I型干扰素反应.
- 评估urolithin A (UA) 在通过线粒细胞活化缓解RP相关炎症方面的治疗潜力.
主要方法:
- 在辐射后建立RP小鼠和BEAS-2B细胞模型.
- 对线粒体损伤,mtRNA释放和RIG-I/MDA5-MAVS通路激活的系统分析.
- 评估UA和Mdivi-1对炎症和肺损伤的影响,包括PINK1/PRKN淘汰研究.
主要成果:
- 辐射诱导线粒体损伤,mtRNA释放,并通过RIG-I/MDA5-MAVS通路通过I型干扰素反应.
- 增加PINK1/PRKN介导的线粒,清除受损的线粒体和减少炎症.
- 乌罗立A治疗改善了肺病理,减少了炎症性细胞因子,并抑制了途径激活,证明了UA的保护作用.
结论:
- 辐射诱导的mtRNA释放触发了I型干扰素反应,加剧了RP炎症.
- 通过清除受损的线粒体和mtRNA,PINK1/PRKN介导的线粒能有效地减少炎症.
- 乌罗立A作为菌诱导剂,对辐射性肺炎具有显著的治疗潜力.
更多相关视频
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.0K
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
296
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
689
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689